Evaluating the safety of PPMX-T003 for aggressive NK-cell leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase I/II dose-escalation study designed to assess the tolerability, safety, efficacy, and pharmacokinetics of the investigational drug PPMX-T003 in patients with aggressive NK-cell leukemia. The study will include patients diagnosed with this condition, regardless of whether it is their first occurrence or a recurrence. The trial aims to gather data on how well the drug works and its safety profile in this specific patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients diagnosed with ANKL (regardless of whether the disease is first or recurrent) based on diagnostic criteria developed with reference to the World Health Organization (WHO) 4th edition (2017) criteria.

Exclusion Criteria:

* Patients eligible to receive chemotherapy as treatment for ANKL

Where it's running

• Hiroshima University Hospital
  Hiroshima, Hiroshima, Japan Recruiting

Study contacts

• Study coordinator: Kiyoshi Ando
• Email: andok@keyaki.cc.u-tokai.ac.jp
• Phone: +81 82-257-5555

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Epstein-Barr virus–positive T/NK-cell lymphoproliferative diseases in large patient groups

  This study follows patients with EBV-positive T/NK-cell disorders to see how they present, what treatments are used, and how they respond over time.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07727083

• Registry for individuals with T-cell lymphoma

  This study is gathering information from people with T-cell lymphoma to help researchers learn more about the disease and improve treatments.

  Recruiting at 6 sites Memorial Sloan Kettering Cancer Center · Duarte, California and 25 other locations · NCT05978141

• Evaluating DR-01 for treating specific types of lymphomas

  This study is testing a new treatment called DR-01 to see if it can safely help adults with certain types of lymphomas feel better and fight their cancer.

  Recruiting at 36 sites Phase 1/2 Dren Bio · Birmingham, Alabama and 36 other locations · NCT05475925

• Chemoimmunotherapy and stem cell transplant for NK T-cell leukemia and lymphoma

  This study is testing two different treatment combinations for people with advanced NK-cell leukemia and lymphoma to see which one works better before they receive a stem cell transplant.

  Recruiting at 6 sites Early Phase 1 New York Medical College · Birmingham, Alabama and 5 other locations · NCT03719105

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.